Skip to main content
. 2024 Oct 12;2024:6142211. doi: 10.1155/2024/6142211

Figure 1.

Figure 1

Overview of the study periods. AT = as-treated; DPP-4i = dipeptidyl peptidase-4 inhibitor; MA = marketing authorization; PS = propensity score; SGLT2i = sodium-glucose cotransporter-2 inhibitor. 1In analyses investigating effectiveness outcomes, the occurrence of the outcome in question was observed until the end of the follow-up (e.g., while investigating hospitalization for heart failure, the follow-up did not end at the occurrence of a stroke).